Literature DB >> 22429346

Targeted drug regulation on methylation of p53-BAX mitochondrial apoptosis pathway affects the growth of cholangiocarcinoma cells.

X-F Liu1, H Jiang, C-S Zhang, S-P Yu, Z-Q Wang, H-L Su.   

Abstract

OBJECTIVE: To study the mechanism of 5-aza-2-deoxycytidine (DAC; a methylation inhibitor) on growth of the human cholangiocarcinoma QBC939 cell line.
METHODS: A colourimetric assay was used to detect growth of QBC939 cells treated with DAC (0.1-100 μmol/l) over 24 h, 48 h and 72 h. Cell morphology was observed by transmission electron microscopy (TEM). The cell cycle and apoptosis were analysed by flow cytometry. Hypermethylation of the promoters of the p53-BAX mitochondrial apoptosis genes cyclin-dependent kinase inhibitor 2A (CDKN2A), death-associated protein kinase 1 (DAPK1) and PYD and CARD domain containing (PYCARD) was detected by methylation-specific polymerase chain reaction, with and without DAC treatment.
RESULTS: DAC inhibited QBC939 cell growth with a half maximal inhibitory concentration of 5 μmol/l at 72 h. After DAC treatment, apoptosis was observed by TEM. Flow cytometric analysis of propidium iodide-positive cells demonstrated increased apoptosis of DAC-treated QBC939 cells (43.04%) compared with untreated cells (4.31%). DAC treatment resulted in demethylation of the gene promoters of CDKN2A and DAPK1 in QBC939 cells.
CONCLUSIONS: DAC induces apoptosis of QBC939 cells by reactivation of hypermethylated p53-BAX mitchondrial apoptosis genes in cholangiocarcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22429346     DOI: 10.1177/147323001204000107

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  7 in total

1.  In vitro neuraotropic growth of cholangiocarcinoma: an experimental study.

Authors:  Yu-Xue Wang; Wei Liu; Xin-Yu Tan; Hui-Huan Tang
Journal:  JRSM Short Rep       Date:  2013-09-13

2.  Cordyceps militaris induces tumor cell death via the caspase‑dependent mitochondrial pathway in HepG2 and MCF‑7 cells.

Authors:  Jingjing Song; Yingwu Wang; Meiyu Teng; Shiqiang Zhang; Mengya Yin; Jiahui Lu; Yan Liu; Robert J Lee; Di Wang; Lesheng Teng
Journal:  Mol Med Rep       Date:  2016-04-25       Impact factor: 2.952

Review 3.  Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma.

Authors:  Toshiaki Nakaoka; Yoshimasa Saito; Hidetsugu Saito
Journal:  Int J Mol Sci       Date:  2017-05-23       Impact factor: 5.923

4.  5-Azacytidine treatment induces demethylation of DAPK1 and MGMT genes and inhibits growth in canine mammary gland tumor cells.

Authors:  Xiaoli Ren; Huatao Li; Xianyi Song; Yuhong Wu; Yun Liu
Journal:  Onco Targets Ther       Date:  2018-05-15       Impact factor: 4.147

Review 5.  Cholangiocarcinoma: Present Status and Molecular Aspects of Diagnosis.

Authors:  Xiao-Fang Liu; Kun Tang; Lu-Lu Sui; Gang Xu
Journal:  Oncol Res       Date:  2014       Impact factor: 5.574

6.  Expression of miR-195 and its target gene Bcl-2 in human intervertebral disc degeneration and their effects on nucleus pulposus cell apoptosis.

Authors:  Xue-Lin Lin; Zhao-Yun Zheng; Qing-Shan Zhang; Zhen Zhang; You-Zhi An
Journal:  J Orthop Surg Res       Date:  2021-06-28       Impact factor: 2.359

Review 7.  Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma.

Authors:  Yu-Chan Chang; Ming-Huang Chen; Chun-Nan Yeh; Michael Hsiao
Journal:  Biomolecules       Date:  2020-09-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.